Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations
- 23 December 2010
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 116 (26), 5832-5837
- https://doi.org/10.1182/blood-2010-08-304725
Abstract
Platelet transfusion is currently the primary medical treatment for reducing thrombocytopenia in patients with inherited thrombocytopenias. To evaluate whether stimulating megakaryopoiesis could increase platelet count in these conditions, we treated patients with a severe thrombocytopenia induced by MYH9 mutations (MYH9-related disease) with a nonpeptide thrombopoietin receptor agonist, eltrombopag. Twelve adult patients with MYH9-RD and platelet counts of less than 50 × 109/L received 50 mg of eltrombopag orally per day for 3 weeks. Patients who achieved a platelet count higher than 150 × 109/L stopped therapy, those with 100 to 150 platelets × 109/L continued treatment at the same eltrombopag dose for 3 additional weeks, while those with less than 100 platelets × 109/L increased the eltrombopag dose to 75 mg for 3 weeks. Major responses (platelet count of at least 100 × 109/L or 3 times the baseline value) were obtained in 8 patients, minor responses (platelet counts at least twice the baseline value) in 3. One patient did not respond. Bleeding tendency disappeared in 8 of 10 patients with bleeding symptoms at baseline. Mild adverse events were reported in 2 patients. The availability of thrombopoietin mimetics opened new prospects in the treatment of inherited thrombocytopenias. This study is registered at www.clinicaltrials.gov as NCT01133860 (European Union Drug Regulating Authorities Clinical Trials number 2008-001903-42).Keywords
This publication has 21 references indexed in Scilit:
- Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopeniaJournal of Thrombosis and Haemostasis, 2009
- Congenital Amegakaryocytic Thrombocytopenia and Thrombocytopenia with Absent RadiiHematology/Oncology Clinics of North America, 2009
- Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITPBlood, 2009
- MYH9-Related Platelet DisordersSeminars in Thrombosis and Hemostasis, 2009
- Megakaryocytes of patients with MYH9-related thrombocytopenia present an altered proplatelet formationThrombosis and Haemostasis, 2009
- Wiskott-Aldrich syndromeCurrent Opinion in Hematology, 2008
- Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history ofMYH9-related diseaseHuman Mutation, 2007
- Altered cytoskeleton organization in platelets from patients with MYH9‐related diseaseJournal of Thrombosis and Haemostasis, 2005
- MYH9-Related DiseaseMedicine, 2003
- Novel treatment modalities: new platelet preparations and subsititutesBritish Journal of Haematology, 2001